Longeveron Secures USPTO Patent For MSC Therapy Targeting Female Sexual Dysfunction

• The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to female patients with sexual dysfunction in order to increase sexual quality of life
• Female sexual dysfunction is an extremely common unmet medical need which can have a major impact on quality of life in otherwise healthy women
• Longeveron anticipates entering into licensing or partnering agreements for the potential development and commercialization of stem cell therapy for this indication
   

MIAMI, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the United States Patent and Trademark Office (USPTO) has granted a patent covering administration of the Company's proprietary mesenchymal stem cells (MSCs) for the treatment of female patients with sexual dysfunction and improvement in sexual quality of life.

U.S. Patent No. 12,496,316, entitled "Treatment of Sexual Dysfunction and Improvement in Sexual Quality of Life," provides Longeveron with patent rights in the United States through 2038. Further patent term extension may occur along with regulatory exclusivity extensions.